Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium Respimat in Severe Persistent Asthma
NCT00772538Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2008
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Tiotropium 5mcg with Placebo (2 arms). Primary endpoints: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h), Trough FEV1 Response at 24 weeks and 1 more. Started Oct 2008; status: completed.
02
Drugs
tiotropium
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00772538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00772538.